A retrospective analysis of metaplastic triple negative breast cancer response to sacituzumab govitecan and candidacy for targeted therapy. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback